Changli Wang

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 293 citations

Medicine, Oncology, Pharmacology +13

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen et al. · Journal of Clinical Oncology · 2019 · 267 citations

Medicine, Oncology, Pharmacology +15

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

Leina Sun, Qiang Zhang, Huanling Luan et al. · Journal of Experimental & Clinical Cancer Research · 2011 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).

Caicun Zhou, Yi‐Long Wu, Xiaoqing Liu et al. · Journal of Clinical Oncology · 2012 · 79 citations

Medicine, Pharmacology, Cancer Pharmacology +7